Pharmacokinetics and pharmacodynamics of ertapenem: an overview for clinicians | Zendy

David E. Nix | Zendy; Anup Majumdar | Zendy; Mark J. DiNubile | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Pharmacokinetics and pharmacodynamics of ertapenem: an overview for clinicians

Author(s) -

David E. Nix,

Anup Majumdar,

Mark J. DiNubile

Publication year - 2004

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkh205

Subject(s) - ertapenem , medicine , carbapenem , pharmacodynamics , antibiotics , pharmacokinetics , pneumonia , dosing , urinary system , intensive care medicine , pharmacology , meropenem , antibiotic resistance , microbiology and biotechnology , biology

Ertapenem, a Group 1 carbapenem, is a once-a-day parenteral beta-lactam antibiotic recently licensed in the USA and Europe. Monotherapy with ertapenem dosed as 1 g once a day has been shown to be highly effective in clinical trials for the treatment of complicated infections of skin and skin structures, complicated intra-abdominal infections, community-acquired pneumonia, acute pelvic infections and complicated urinary tract infections. Dosing modifications have not been recommended for adults on the basis of gender, age, weight or liver disease. Presently there are no data regarding the use of ertapenem in children. Dose reductions are indicated for patients with advanced renal insufficiency. Ertapenem is neither a substrate nor an inhibitor of P-glycoprotein or cytochrome P450 enzymes; significant drug interactions between ertapenem and drugs handled by these systems are not expected.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research